UNSPSC 51312210: Rupatadine fumarate

This classification denotes a histamine-1 receptor antagonist C26H26ClN3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XJ6OT32M93, chemically known as 5h-benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-, (2e)-2-butenedioate (1:1), but more generally known as rupatadine fumarate, which bears US NIH Compound Identifier 6449107.

European Medicines Agency schedules Rupatadine fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22090. Most nations, for tariff and trade purposes, schedule rupatadine fumarate under HS 29333999 and SITC 51574. As of Q4 2014, RUPATADINE FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC(CNC1)CN2CCC(=C3C4CCC(CC4CCC5C3NCCC5)CL)CC2.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51312210 Rupatadine fumarate is a Commodity code that designates a specific pharmaceutical active ingredient, but recent state and local procurement activity tagged to this code does not reflect purchases of rupatadine fumarate itself. Instead, issuing bodies are using the code to solicit naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription fulfillment programs—a mismatch that signals the code has limited relevance to current state and local buying patterns. The work actually being procured under this code involves acquisition of finished pharmaceutical products and pharmacy benefit management services across health departments, cooperative purchasing alliances, and state health agencies, rather than sourcing a single active pharmaceutical ingredient. Issuing bodies range from county health departments and state health and human services commissions to multistate cooperative purchasing organizations, with repeat participation from state procurement offices and regional health authorities.

Recent activity is concentrated in the Upper Midwest and Southeast. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, including Oregon, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus optional one-year renewal. The code shows limited relevance to actual pharmaceutical ingredient procurement; firms should assess whether opportunities tagged to this commodity actually align with their product portfolio before pursuing.